Loading clinical trials...

Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder

A Multi-Centre, Double-Blind, Randomised, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SRTM) in Combination With an Antidepressant in the Treatment of Patients With Major Depressive Disorder With Inadequate Response to an Antidepressant Treatment

NCT00351910•AstraZeneca

View on ClinicalTrials.gov

Summary

To evaluate the efficacy of quetiapine fumarate sustained release (Seroquel SR™) in combination with an antidepressant versus an antidepressant alone in patients with Major Depressive Disorder. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Male or female aged 18 to 65 years
•A documented diagnosis of major depressive disorder

Exclusion Criteria

•Patients with a DSM IV Axis I disorder other than MDD within 6 months of enrolment
•Patients with a diagnosis of DSM IV Axis II disorder which has a major impact on the patient's current psychiatric status
•Patients whose current episode of depression exceeds 12 months or is less than 4 weeks prior to enrolment

Locations (72)

Research Site

Everton Park, Queensland, Australia

Research Site

Southport, Queensland, Australia

Research Site

Frankston, Victoria, Australia

Research Site

Malvern, Victoria, Australia

Research Site

Prahran, Victoria, Australia

Research Site

Richmond, Victoria, Australia

Research Site

Brisbane, Australia

Research Site

Assebroek, Belgium

Research Site

Brussels, Belgium

Research Site

Ghent, Belgium

Key Dates

Start Date

May 1, 2006

Completion Date

April 1, 2007

Last Updated

January 26, 2011

Enrollment

494

ACTUAL participants

Conditions

Major Depressive Disorder

Interventions

Quetiapine

DRUG

Amitriptyline

DRUG

Bupropion

DRUG

Citalopram

DRUG

Duloxetine

DRUG

Escitalopram

DRUG

Fluoxetine

DRUG

Paroxetine

DRUG

Sertraline

DRUG

Venlafaxine

DRUG

A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

NCT07115329

Major Depressive Disorder

View study

RECRUITINGPHASE3

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

NCT06793397

Major Depressive Disorder (MDD)Depression in Adults+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 26, 2011Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder

Inclusion Criteria

Exclusion Criteria

A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

Accelerated Intermittent Theta Burst Stimulation for Adolescent and Young Adult Depression With Elevated Suicide Risk

Validating the On-line Creyos Cognitive Assessment Platform in Older Adults With Major Depressive Disorder or Mild Cognitive Impairment

University of Iowa Interventional Psychiatry Service Patient Registry

Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)